Direct-to-consumer advertising of pharmaceuticals: Developed countries experiences and Turkey

Health Expectations

Volumn 10, Issue 1, 2007, Pages 4-15

  Semin, Semih ^a   Aras, Şahbal ^a   Guldal, Dilek ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Direct to consumer advertising; Drug information; Drug promotion

Indexed keywords

CONSUMER; DEVELOPED COUNTRY; DRUG INDUSTRY; DRUG MARKETING; INTERNET; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; TURKEY (REPUBLIC); WORLD HEALTH ORGANIZATION;

ADVERTISING; CONSUMER PARTICIPATION; DEVELOPING COUNTRIES; DRUG INDUSTRY; TURKEY;

EID: 33847263033     PISSN: 13696513     EISSN: 13697625     Source Type: Journal    
DOI: 10.1111/j.1369-7625.2006.00411.x     Document Type: Review

References (115)

1. Raven M. Direct-to-consumer advertising: Healthy education or corporate spin? Healthy Skepticism International News 2004; 22: http://www.healthyskepticism.org/news/issue.php?id=5 (accessed 22 May 2005).
2. Gardner DM, Mintzes B, Ostry A. Direct-to consumer prescription drug advertising in Canada: permission by default? Canadian Medical Association Journal, 2003; 169: 425-427.
3. Meek C. Direct-to-Consumer Advertising of Prescription Medicines: A Review of International Policy and Evidence. A Report for the Royal Pharmaceutical Society of Great Britain 2001 (November). http://www.rpsgb.org.uk/pdfs/dtcarep.pdf (accessed 11 May 2004).
4. Toop L, Richards D, Dowell T, Tilyard M, Fraser T, Arroll B. Direct to Consumer Advertising of Prescription Drugs in New Zealand: For health or for Profit? NewZealand 2003. http://www.chmeds.ac.nz/report.pdf (accessed 1 May 2005).
5. Belkin L. Prime Time Pushers (March/April, 2001). http://www.motherjones.com/magazine/MA01/drug.html (accessed 1 May 2005).
6. WHO. Ethical Criteria for Medicinal Drug Promotion. Geneva: World Health Organisation, 1988.
7. Official Paper. İspençiyari ve Tibbi Müstahzarlar Kanunu. Resmi Gazete, 1928. http://www.recete.org/yasalar/yasa09.php (accessed 22 December 2003).
8. Official Paper. Radyo ve Televizyonlarin Kuruluş ve Yayinlar Hakkinda Kanun (3984). Resmi Gazete, 1994. 13 Nisan: 219111.
9. Semin S. Sosyal ve Ekonomik Yönleriyle İlaç . Ankara: TTB Yayinlari, 1998.
10. Official Paper. Beşeri Tibbi ürünlerin Tanitim Faaliyetleri Hakkinda Yönetmelik. Resmi Gazete, 2003; 25268: 29-34.
11. Arslan L. Ilica Saǧlik Ocaǧina başvuran hastalarin reçetede yazilan ilaçlari kullanimi ve bunu etkileyen etmenler. İzmir: Dokuz Eylül Üniversitesi Halk Saǧliǧi Anabilim Dali Uzmanlik Tezi, 2003.
12. IMS Health. http://www.pharmexec.com/pharmexec/data/articlestandard/ pharmexec/282005/169778/article.pdf (accessed 1 May 2006).
13. CAM Group News. 25 March 2005-4(4). http://csd.cam-group.com/www_assets/ pages/downloads/CAMNewsletterQ404.pdf (accessed 1 May 2006).
14. Relman AS, Angell M. America's other drug problem. The New Republic, 2002; 16: 27-41.
15. Martiweb. 'Kiyak' promosyon (NTVMSNBC-21.11.2003). http://www. martiyazilim.com.tr/marti.php?yol=haberler/yasam/2003_4/kiyakpromosyon.htm (accessed 12 May 2005).
16. Şemin S, Aras Ş. Temel Yönleriyle Psikiyatride Etik. İzmir: Dokuz Eylül Yayinlari, 2004.
17. Arnold M. 5 Factors driving direct marketing. Medical Marketing & Media, 2003; June: 38-49. http://offlinehbpl.hbpl.co.uk/Misc/MMM/ Features/603%20DIRECT%20MARKETING%2038-49.pdf (accessed 1 May 2006).
18. Angell M. The truth about the drug companies. The New York Review of Books, 2004; 51: 15. http://www.nybooks.com/articles/17244 (accessed 1 July 2005).
19. Morin K, Rakatansky H, Riddick FA Jr et al. Managing conflicts of interest in the conduct of clinical trials. Journal of the American Medical Association, 2002; 287: 78-84.
20. Cockburn IM. The changing structure of the pharmaceutical industry. Health Affairs 2004; 23: 10-22.
21. İEİS. Aylik Rapor. 2004. Mart 115. http://www.ieis.org/ tr/yayin/index2.htm (accessed 2December 2004).
22. IMS Health Reports. Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion (March 21, 2006). http://www.imshealth.com/ims/ portal/front/articleC/0,2777,6599_3665_77491316,00.html (accessed 2 May 2006).
23. IMS. Global Pharmaceutical Sales, 1998-2005 (February 27, 2006). http://www.imshealth.com/ims/portal/front/articleC/0,2777, 6599_77478579_77478598,00.html (accessed 2 May 2006).
24. WHO. Comparative Analysis of National Drug Policies: Second Workshop (Geneva, 10-13 June 1996). http://whqlibdoc.who.int/hq/1997/ WHO_DAP_97.6.pdf (accessed 12 July 2004).
25. IEIS (Pharmaceutical Manufacturers Association of Turkey). Ilaç, 101 Soru, 101 Yanit. Istanbul, 1989.
26. IMS. Lipitor Leads the Way in 2003 (March 18, 2004). http://www.imshealth.com/web/content/0,3148,64576068_63872702_70260998_70960214, 00.html (accessed 14 October 2004).
27. Akyildiz A. 2003 yilinda ilaç pazari. Hedef Saǧlik, 2004. http://www.hedefim.com/v3/hs/18/10.asp (accessed 23 December 2004).
28. Neville S. Sales force effectiveness. The new strategic imperative. European Pharmaceutical Executive (Jan 2004). http://www.europharmexec. com/europharmexec/article/articleDetail.jsp?id=82791 (accessed 2 October 2005).
29. Brand R, Kumar P. Detailing gets personal - integrated segmentation may be pharma's key to 'repersonalizing' the selling process. Pharmaceutical Executive (August 2003). http://www.imshealth.com/vgn/images/portal/ cit_40000873/43673451Integrated_Segmentation.pdf (accessed 1 May 2006).
30. Drews J. Strategic trends in the drug industry. Drug Discovery Today, 2003: 8: 411-420.
31. Eyeforpharma. Sales Force Effectiveness: Getting it Right (December 2004). http://faculty.fuqua.duke.edu/~willm/Classes/Pharma2005/Materials/ 00_BG/SalesForce/Sales%20Force%20Effectiveness%20report.pdf (accessed 2 May 2006).
32. Garg R, Gueco M, Hancock A, LeVee S, Srinivasan A. An Assessment of the Present Sales Force Model on U.S. Pharmaceutical Marketing Efforts. (14 March 2005). http://www.kellogg.northwestern.edu/academic/biotech/articles/ sales_force_model.pdf (accessed 1 May 2006).
33. Elling ME, Fogle HJ, McKhann CS, Simon C. Making more of pharma's sales force. The McKinsey Quarterly, 2002; 3: 86. http://www.euractiv. com/Article?tcmuri=tcm:29-117616-16&type=Analysis (accessed 3 May 2006).
34. cSemin S, Aras cS. İlaç ve promosyon. Toplum ve Hekim, 2004; 19: 350-358.
35. Göktaş G. İlaç sektöründe pazarlama stratejileri ve kişisel satiş yönteminin tanitim ve satiş üzerine etkisi. İzmir: Dokuz Eylül Üniversitesi Sosyal Bilimler Enstitüsü Yüksek Lisans Tezi, 2003.
36. Acar K, Zencir M, Özşahin A. Hekimlerin ilaç firma temsilcileriyle ilişkilerinde etik sorunlar. Ulusal Tibbi Etik Kongresi Kitabi, 1999; 1: 85-88.
37. Ekiyor A. İlaç pazarlamasinda tibbi satiş temsilcileri ile hekimler arasinda karşilaşilan sorunlarin tespitine yönelik bir alan çal?şmasi. Ankara: Gazi Üniversitesi Sosyal Bilimler Enstitüsü Yüksek Lisans Tezi, 2001.
38. Brekke KR, Kuhn M. Direct-to-consumer advertising in pharmaceutical markets, 2002. http://heb.rokkan.uib.no/publications/files/87Notat09_03.pdf (accessed 14 February 2005).
39. Lancet. Europe on the brink of direct-to-consumer drug advertising (Editorial). Lancet, 2002; 359: 1709-1710.
40. Moynihan R, Smith R. Too much medicine? Almost certainly. British Medical Journal, 2002; 324: 859-860.
41. Kocaeli Tabip Odasi. 2003 yili birinci basamaǧa yönelik tani ve tedavi rehberinin 2005 yili bütçe uygulama talimati taslaǧi'na göre incelenmesi (November 2004). http://www.kocaelitabip.org.tr/haberler/butceuygulama.pdf (accessed 4 March 2006).
42. Morgan S. An Assessment of the Health System Impacts of Direct-to-consumer Advertising of Prescription Medicines (DTCA). Volume V: Predicting the Welfare and Cost Consequences of Direct-to-Consumer Prescription Drug Advertising (August 2001). http://www.chspr.ubc.ca/hpru/pdf/dtca-v5- econ.pdf (accessed 2 October 2004).
43. Kumar P, Zaugg AM. IMS review: steady but not stellar. Medical Marketing & Media, 2003; May: 50-63. http://www.imshealth.com/ vgn/images/portal/cit_40000873/42912029Business%20Watch.pdf (accessed 2 November 2004).
44. Matthews M. Who's Afraid of Pharmaceutical Advertising? IPI Policy Report. 155 (17 May 2001) http://www.ipi.org/ipi%5CIPIPublications.nsf/ PublicationLookupFullText/F4F61FB6BB576D4086256A4F00229C21 (accessed 13 November 2004).
45. Sabah. Tehlikeli ecz@ne (24 June 2005). http://www.sabah.com.tr/2005/06/ 24/gun114.html (accessed 1 May 2006).
46. Wolfe SM. Direct-to-consumer advertising-education or emotion promotion? New England Journal of Medicine, 2002; 346: 524-526.
47. Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. New England Journal of Medicine, 2005; 352: 325-328.
48. Medawar C. Providing prescription medicine information to consumers: is there a role for direct-to-consumer promotion? HAI Europe, 2002. http://www.haiweb.org/campaign/DTCA/symposium_reports.html (accessed 11 May 2004).
49. Bell RA, Wilkes MS, Kravitz RL. The educational value of consumer-targeted prescription drug print advertising. Journal of Family Practice, 2000; 49: 1092-1098.
50. Lyles A. Direct marketing of pharmaceuticals to consumers. Annual Review of Public Health, 2002; 23: 73-91.
51. NTVMSNBC. Kadinlar daha çok vitamin kullaniyor. http://www.ntvmsnbc.com/news/322829.asp (accessed 28 May 2005).
52. Giritoǧlu H. İlaç reklaminda tek beklenti kar. Tip Dünyasi, 2004; 117: 2. (1 March 2004).
53. Kinikoǧlu M. Aspirin meselesine noktayi koyuyorum. http://www.aksam.com.tr/arsiv/aksam/2005/06/30/yazarlar/yazarlar343.html (accessed 3 May 2006).
54. Farmamedya. Calcium Sandoz vit C'den TV'de gizli reklam mi? (10 January 2005) http://www.farmamedya.com/index.php?module=yazilar&num= 9766527f2b5d3e95d4a733fcfb77bd7e (accessed 3 May 2006).
55. Baydar Y. İlaçlarda reklam. Milliyet (16 October 2000).
56. Aral İ. İçimden Kuşlar Göçü yor. Istanbul: Can Yayinlari, 1999.
57. Medimagazin. Ücretsiz taramalara paydos. Medimagazin, 166 (23 February 2004).
58. Radikal. 'Hiperaktif' tartişma. Radikal (23 December 2003).
59. Mintzes B. Promotion targeting consumers (Chapter 1). Blurring the Boundaries: New Trends in Drug Promotion (HAI- Europe 1998). http://www.haiweb.org/pubs/blurring/blurring.intro.html (accessed 4 May 2002).
60. Medimagazin. Zyban'in ruhsati askida. Türkiye Klinikleri, 2002; 94. http://www.medimagazin.com.tr/haber_31361.html (accessed 1 May 2006).
61. Rosenthal MB, Berndt ER, Donuhue JM, Epstein AM, Frank RG. Demand effects of recent changes in prescription drug promotion. Kaiser Family Foundation, 2003. http://www.kff.org/rxdrugs/6085-index.cfm (accessed 2 October 2004).
62. Iizuka T, Jin GZ. The effects of direct-to-consumer advertising in the prescription drug market (15 October 2002). http://www.cramton.umd.edu/workshop/ papers/jin-direct-drug-advertising.pdf (accessed 21 November 2005).
63. Lexchin J, Mintzes B. Direct-to-consumer advertising of prescription drugs: the evidence says no. Journal of Public Policy and Marketing, 2002; 21: 194-201.
64. İEİS. Aylik Rapor. 1991; 36-37; 1-8.
65. Espicom Business Intelligence. World Pharmaceutical Markets (September 2002) (France). http://news.investinfrance-nordic.org/1/txt/ Pharma%20in%20France.pdf (accessed 1 May 2005).
66. VFA. The Pharmaceutical Market in Germany. German Associations of Research Based Pharmaceutical Companies, 2003. http://www.vfa.de/en/ statistics/pharmaceuticalmarket/ (accessed 12 December 2004).
67. Tokat M. Türkiye Saǧlik Harcamalari ve Finansmani 1998. Ankara: Saǧlik Bakanliǧi, Saǧlik Projesi Genel Koordinatörlüǧü, 2001.
68. DPT. Ekonomik ve sosyal göstergeler. http://ekutup.dpt.gov.tr/ ekonomi/gosterge/tr/ (accessed 11 February 2004).
69. WHO. The World Medicines Situation, 2004. http://w3.whosea.org/ LinkFiles/Reports_World_Medicines_Situation.pdf (accessed 10 December 2004).
70. Şemin S. 1980'den günümüze saǧlik alaninda deǧişimler. Bülten, 1991, Ekim.
71. World Bank. Reforming the Health Sector for Improved Access and Efficiency. Report No. 24358-TU. 2003. (31 March 2003) (Turkey - Projects & Programs). http://www.worldbank.org.tr (accessed 4 July 2005).
72. Rokstad K, Straand J, Fugelli P. General practitioners' drug prescribing practice and diagnoses for prescribing: the More & Romsdal Prescription Study. Journal of Clinical Epidemiology, 1997; 50: 485-494.
73. Burt C. National trends in use of medications in office-based practice, 1985-1999. Health Affairs, 2002; 21: 206-214.
74. Mollahaliloǧlu S, Tezcan S. Ankara il merkezinde bulunan saǧlik ocaklarindan saǧlik hizmeti alan hastalarin akilci ilaç kullanimi açisindan deǧerlendirilmesi. Ulusal Halk Saǧliǧi Kongresi Bildiri Kitabi, 2002; 8: 517-520.
75. Eliya R, Jayawardhane P, Karunaratne L. Private Primary Care Practitioners in Sri Lanka (2003). http://lnweb18.worldbank.org/sar/sa.nsf/ %20%20Attachments/chapt11/$File/11_Yazbeckfinal.pdf (accessed 14 May 2004).
76. Algan E. Asabiyetimiz arttikca antidepresana sarildik. Vatan (16 April 2004).
77. Ege. Antibiyotik hastaliǧi. Cumhuriyet (30 May 1989).
78. WHO. Access to Essential Drugs for Priority Health Problems. Health Organization, 2000. http://www.slidebay.com/search.php?search= Essential+drugs (accessed 5 May 2006).
79. Coşkun Ö. Akilci ilaç kullanimi. 8. Pratisyen Hekimlik Kongresi. Kongre Programi ve Özet Kitabi, 2003. pp 54-55.
80. Mollahaliloǧlu S. Türkiye'de akilci ilač uygulamalari. SB Diyalog, 2005; 12: 12-16.
81. Aydin S. İlaç: dert mi deva mi? SB Diyalog, 2005; 12: 18-19.
82. MH (Ministry of Health). Pharmaceutical prices. 2004. http://www.saglik.gov.tr/sb/default.asp?sayfa=birimler&cid=1&sid=977 (accessed 22 July 2004).
83. Coşkun N. Bakkallar eczane gibi. Milliyet (24 February 2004).
84. Fisher M. Physician and the pharmaceutical industry - a dsysfunctional relationship. Perspectives in Biology and Medicine, 2003; 46: 254-272.
85. Washburn J. Undue influence. The American Prospect (13 August 2001). http://www.prospect.org/print/V12/14/washburn-j.html (accessed 12 December 2004).
86. Working Group on Women and Health Protection. Direct-to-consumer advertising of prescription drugs. 2002. http://www.cewh-cesf.ca/PDF/whp/dtca- consultation.pdf (accessed 5 December 2004).
87. NIHCM.Prescription drugs and mass media advertising, 2000 (A research report) National Institute for Health Care Management. 2001. http://www.nihcm.org/DTCbrief2001.pdf (accessed 2 October 2004).
88. Lenzer J. FDA is incapable of protecting US 'against another Vioxx'. British Medical Journal, 2004; 329: 1253.
89. Köylü H. Türkiye yan etkiden bihaber. Radikal (14 May 2002).
90. Mello MM, Rosenthal M, Neumann PJ. Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers. Journal of the American Medical Association, 2003; 289: 477-481.
91. Göçmen E, Göçmen A. İlaç ve hukuk. 2003. http://www.hukuki.net/www.saglikhukuku.net/bilgi/a046.asp (accessed 21 November 2004).
92. Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Affairs, 2003; Jan-Jun: Suppl. Web Exclusives W3 82-95.
93. Terzian TV. Direct-to-consumer prescription drug advertising. American Journal of Law & Medicine, 1999; 1: 149-167.
94. Mansfield PR, Mintzes B, Richards D, Toop L. Direct to consumer advertising. British Medical Journal, 2005; 330: 5-6.
95. Akici A, Uǧurlu MÜ, Gönüllü N, Oktay Ş, Kalaça S. Pratisyen hekimlerin akilci ilaç kullanimi konusunda bilgi ve tutumlarinin deǧerlendirilmesi. Sürekli Tip Eǧitimi Dergisi, 2002; 11: 253-256.
96. Oǧuz Y. Psikiyatride onam ve aydinlatilmiş onam. Ankara: Ankara Üniversitesi, Saǧlik Bilimleri Enstitüsü Doktora Tezi, 1994.
97. Deveugele M, Derese A, van den Brink-Muinen A, Bensing J, De Maeseneer J. Consultation length in general practice: cross sectional study in six European countries. British Medical Journal, 2002; 325: 472.
98. Sleath B, Roter D, Chewning B, Svarstad B. Asking questions about medication: analysis of physician-patient interactions and physician perceptions. Medical Care, 1999; 37: 1169-1173.
99. Council of Europe. Self-medication and the pharmacist. Pharmaceutical Journal 1999; 263: 718-720. http://www.pharmj.com/Editorial/19991030/ forum/councilofeurope.html (accessed 21 December 2004).
100. Mintzes B. Direct to consumer prescription drug advertising. The European Comission's Proposals for Legislative Change. 2001. (HAI-Europe, December 2001). http://www.haiweb.org/campaign/DTCA/BMintzes_en.pdf (accessed 11 May 2004).
101. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. New England Journal of Medicine, 2002; 346: 498-505.
102. TTB. Keşiften kullanima ilaç. Türk Tabipleri Birliǧi Görüşleri. 2002. http://www.ttb.org.tr/ilac/ kesif.htm (accessed 12 December 2004).
103. DİE. Nüfus ve kalkinma göstergeleri. 2003. http://nkg.die.gov.tr/goster.asp?aile=3 (accessed 21 January 2004).
104. Roses A. Drugs 'don't work on many people' (8 December 2003). http://news.bbc.co.uk/1/hi/health/3299945.stm (accessed 1 March 2006).
105. İnterpharma. Swiss Health Care and Pharmaceutical Market. 2002. http://www.interpharma.ch/info/wissens/health_market/pdf/HealthCare02.pdf (accessed 16 April 2004).
106. Office for National Statistics. Health spending revealed. Economic Trends March. 2003. http://www.statistics.gov.uk/pdfdir/ect0303.pdf (accessed 2 October 2004).
107. Anderson GF, Petrosyan V, Hussey PS. Multinational comparisons of health systems data. 2002. http://www.cmwf.org/programs/international/ anderson_multinationalcomparisons2002_582.pdf (accessed 21 February 2003).
108. Uras G. Grip aşisi hem Ayşe Teyze hem de ekonomi için önemli. Milliyet (28 November 2004).
109. Avorn J. Advertising and prescription drugs: Promotion, education, and the public's health. Health Affairs, Web Exclusive, 2003; 26: 104-108.
110. Mintzes B. Direct-to-consumer advertising of prescription drugs - whatever the problem, you can always pop a pill. Research Bulletin, 2003; 3. http://www.cewh-cesf.ca/bulletin/v3n2/page5.html (accessed 2 June 2004).
111. Woloshin S, Schwartz LM, Jenniver T, Welch HG. Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet, 2001; 358: 1141-1146.
112. Radikal. İlaca AB standardi geldi. Radikal, 2003 (24 October 2003).
113. Arslanoǧlu K. Avrupa Birliǧi bize saǧlik kazandiracak mi? Tip Dünyasi, 2004 (1 March 2004).
114. Savaş S, Karahan Ö, Saka Ö. Health system in transition Turkey. European Observatory on Health Care Systems, 2002; 4: 58.
115. EU. European Parliament and of the Council of the European Union Directive 2001/83/EC. http://www.opbw.org/nat_imp/leg_reg/uk/ec_dir_2001_83.pdf (accessed 2 December 2005).